Faculty profile

Lee Mozessohn

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Lee Mozessohn

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
34 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Latest papers

Grip strength is associated with overall survival in myelodysplastic syndrome.
Blood advances · 2026
A hemoglobin >120g/L trends toward improved survival without increasing vascular events in ESA-treated MDS patients.
Blood advances · 2026
Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma.
Journal of the National Cancer Institute · 2026 · senior author

All 46 publications

Latest funding

Early discontinuation of antibiotics for unexplained febrile neutropenia: a pilot randomized controlled trial- EASE ANTIBIOTICS pilot trial
CIHR · 2023 · Co-investigator
$512,551
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
CIHR · 2021 · Co-investigator
$100,000
Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work
CIHR · 2020 · Co-investigator
$100,000

All 5 grants and awards

46 publications.

Grip strength is associated with overall survival in myelodysplastic syndrome.

Chornenki NLJ, Mozessohn L, Chodirker L, Chow S, Kennedy JA, England JT, Cheung MC, Geddes M, Sabloff M, Christou G, Fulcher J, Rajendra A, St Hilaire E, Finn N, Zhu NY, Leber B, Garcia-Horton A, Trottier AM, Shamy A, Leitch HA, Houston BL, Landego I, Yee KWL, Nevill TJ, Storring J, Elemary M, Habib LA, Delage R, Siddiqui M, Zhang L, Buckstein RJ

Blood advances2026

DOI: 10.1182/bloodadvances.2026021036 PMID: 42782304

A hemoglobin >120g/L trends toward improved survival without increasing vascular events in ESA-treated MDS patients.

Skorupski C, Chodirker L, Mozessohn L, England JT, Kennedy JA, Cheung MC, Chow S, Teichman J, Goldberg N, Hershenfeld SA, Tsui H, Mamedov A, Siddiqui M, Zhang L, Buckstein RJ

Blood advances2026

DOI: 10.1182/bloodadvances.2026021068 PMID: 42747869

Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma.

Ravindran M, Peng J, Zipursky J, Luo J, Liu N, Chan KKW, Cheung MC, Mozessohn L

Journal of the National Cancer Institute2026Senior author

DOI: 10.1093/jnci/djag305 PMID: 42679364

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

Garcia JS, Desai P, Zeidner JF, Wolach O, LeBlanc TW, Abedin S, Vachhani P, Sweet K, Moshe Y, Pollyea DA, Lai C, Levitz D, Nachmias B, Mozessohn L, Xavier M, Zuckerman T, Konopleva M, Chen EC, Stahl M, Xu Y, Bui CN, Miu K, Schmidt X, Grunspan M, Lin CW, Ma E, Montez M, Guérin A, Burne R, Easson K, Levesque-Leroux M, Baraka E, Goldberg AD

Leukemia & lymphoma2026

DOI: 10.1080/10428194.2026.2696455 PMID: 42525505

American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.

DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani A, Aljurf M, Audino A, Benitez L, Deeter A, Dworkin E, Hiltbrand O, Isenalumhe L, Li L, Miller-Chism C, Mozessohn L, Ng AP, Pu JJ, Shafer D, Madueno FV, Viny A, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock W, Wolfson JA

Blood advances2026

DOI: 10.1182/bloodadvances.2021006469 PMID: 41670627

Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype.

Quon S, Skorupski C, Langlois C, Mozessohn L, Hojilla C, Chen LYC

American journal of hematology2026

DOI: 10.1002/ajh.70284 PMID: 41840344

Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?

Mozessohn L, Buckstein R

Haematologica2026First author

DOI: 10.3324/haematol.2025.288157 PMID: 40568724

Secondary primary malignancies in indolent non‐Hodgkin lymphoma patients receiving frontline bendamustine‐rituximab

Davies GA, Prica A, Ante Z, Liu N, Pond GR, Balitsky AK, Suleman A, Mozessohn L

Cancer20261 citationsSenior author

DOI: 10.1002/cncr.70327

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A

British Journal of Haematology2026

DOI: 10.1111/bjh.70632

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma

Mozessohn L, Villeneuve PJA, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A

Current Oncology2026First author

DOI: 10.3390/curroncol33060366

Something wrong or missing on this profile? Suggest a correction

Lee Mozessohn

Research

Latest papers

Latest funding

Grip strength is associated with overall survival in myelodysplastic syndrome.

A hemoglobin >120g/L trends toward improved survival without increasing vascular events in ESA-treated MDS patients.

Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma.

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.

Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype.

Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?

Secondary primary malignancies in indolent non‐Hodgkin lymphoma patients receiving frontline bendamustine‐rituximab

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma

Early discontinuation of antibiotics for unexplained febrile neutropenia: a pilot randomized controlled trial- EASE ANTIBIOTICS pilot trial

Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting

Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work

Assessment of Cancer Patient and Caregiver Perspective on the Novel Coronavirus (COVID-19) and the Impact on Delivery of Cancer Care at an Institution with a Confirmed Case of COVID-19

Trajectories of Psychosocial and Functional Outcomes among Non-Hodgkin Lymphoma (NHL) Survivors

Frequent collaborators

Ning Liu

Lisa Chodirker

Brian Leber

Mitchell Sabloff

Nicole Mittmann

Danielle Rodin

Versha Banerji

Jeannie Callum

Shabbir Alibhai

Nancy Heddle

John Kuruvilla

Tom Kouroukis

David Spaner

Asher Mendelson

Inna Gong

David Hodgson

Dmitry Rozenberg

Christopher Bredeson

Jonathan Zipursky

Simron Singh

Emily Rimmer

Kelvin Chan

Amaris Karin Balitsky

Gwynivere Davies

Ryan Zarychanski

Gregory Pond

Lisa Hicks

Kevin Imrie

Paul Kurdyak